



Public Health  
England

# Urology Service Profiles

## Site-specific indicators

NCIN SSCRG 7<sup>th</sup> October 2014



# Profiles - rationale

Benchmark and assess

NHS Trust / multi-disciplinary team ( MDT ) based

Assist clinical teams to reflect on outcomes

Assist the commissioners of cancer services to

- *understand the variation across the MDT's (local service) for both patient experience and patient care.*

Indicators included have been

- *discussed with commissioners and clinicians as being important and form the basis for objective dialogue about clinical practice and service delivery.*



Public Health  
England



# What do profiles show?

- Size (Generic)
- Demographics (Generic)
- Specialist Team (Generic)
- Throughput (Generic)
- Waiting Times (Generic)
- Practice (Site Specific)
- Outcomes and Recovery (Site Specific)
- Patient Experience (Generic)




# Example

Section	#	Indicator	No. of patients/ cases or value	Percentage or rate			Trust rate or percentage compared to England		Source	Period					
				Trust	Lower 95% confidence limit	Upper 95% confidence limit	England	Low- est			Range	High- est			
Size	1	Number of newly diagnosed lung cancer patients per year, 2010 [experimental] (1)	304				207	41							
	2	Number of NLCA patients - lung cancer	329				191	1							
	3	Number of NLCA patients - mesothelioma	11				10	0							
Demographics (based on newly diagnosed patients, 2010)	4	Patients (from #1) aged 70+	188	62%	56%	67%	61%	39%				588	NCDR	2010	
	5	Patients (from #1) with recorded ethnicity	295	97%	94%	98%	93%	66%				585	NLCA	2011	
	6	Patients (from #5) with recorded ethnicity which is not White-British	3	1%	0%	3%	7%	0%				31	NLCA	2011	
	7	Patients (from #1) who are Income Deprived (2)		29%			16%	7%				75%	NCDR	2010	
	8	Male patients (from #1)	161	53%	47%	58%	55%	43%				100%	NCDR	2010	
	9	Number and proportion of patients (from #2) with a stage assigned	326	99%	97%	100%	92%	36%				46%	NCDR	2010	
	10	Number and proportion of patients, excluding SCLC, with stage I or II assigned	83	29%	24%	35%	24%	10%				34%	NCDR	2010	
	11	Number and proportion of patients, excluding SCLC, with a stage IIIA assigned	36	13%	9%	17%	14%	4%				72%	NCDR	2010	
	12	Number and proportion of patients, excluding SCLC, with a stage IIIB and IV assigned	167	58%	53%	64%	62%	13%				68%	NLCA	2011	
	13	Proportion of patients (from #2) with a Performance Status assigned	286	87%	83%	90%	89%	2%				30%	NLCA	2011	
Specialist Team	14	Peer review: Does the specialist team have full membership? (3)	SA	Yes										NCDR	2010
	15	Peer review: Proportion of peer review indicators met	SA	85%			89%							NCDR	2010
	16	Peer review: are there immediate risks? (4)	SA	No										NCDR	2010
	17	Peer review: are there serious concerns? (4)	SA	No										NCDR	2010
Throughput and pathology	18	Number and proportion of patients (from #2) seen by CNS (5)	206	63%	57%	68%	79%	0%				100%	NLCA	2011	
	19	Number of urgent GP referrals for suspected cancer	406				293	0				853	CWT	2010/11	
	20	Number and proportion of patients (from #2) with confirmed NSCLC	184	56%	52%	60%	62%	0%				93%	NLCA	2011	
	21	Number and proportion of patients (from #2) with confirmed SCLC	40	12%	9%	16%	12%	0%				100%	NLCA	2011	
	22	Number and proportion of patients (from #2) with confirmed NSCLC who are diagnosed NOS	21	11%	8%	17%	19%	0%				79%	NLCA	2011	
	23	Number and proportion of patients (from #2) with histological confirmation of diagnosis	228	69%	64%	74%	77%	52%				100%	NLCA	2011	
Waiting times	24	Estimated proportion of tumours with emergency presentations [experimental]	94	47%	40%	54%	37%	2%				97%	HES	2011	
	25	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks	135	96%	92%	98%	97%	88%				100%	CWT	2012/13 Q2	
	26	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer	15	73%	52%	87%	80%	0%				100%	CWT	2012/13 Q2	
	27	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	103	25%	21%	30%	24%	4%				46%	CWT	2011/12	
	28	Cases treated that are urgent GP referrals with suspected cancer [experimental]	34	25%	19%	33%	39%	0%				76%	CWT	2011/12	
	29	Q2 2012/13: First treatment began within 31 days of decision to treat	14	100%	78%	100%	99%	91%				100%	CWT	2012/13 Q2	
Practice	30	No. and proportion of patients (from #2) receiving surgery, chemotherapy and/or radiotherapy	174	53%	47%	58%	60%	36%				100%	NLCA	2011	
	31	No. and proportion resected of patients (from #2) excluding confirmed SCLC	50	17%	13%	22%	16%	0%				38%	NLCA	2011	
	32	No. and proportion resected of patients (from #2) with confirmed NSCLC	48	26%	20%	33%	21%	0%				45%	NLCA	2011	
	33	No. and proportion resected of patients (from #2), excluding confirmed SCLC, with stage I and II disease	40	48%	38%	59%	53%	0%				100%	NLCA	2011	
	34	No. and proportion of patients (from #2) with confirmed SCLC receiving chemotherapy	27	68%	52%	80%	68%	0%				100%	NLCA	2011	
	35	No. and prop. of patients (from #2) with stage IIIB/IV, PS 0-1 excl. conf. SCLC, receiving chemotherapy	28	58%	44%	71%	55%	0%				100%	NLCA	2011	
Outcomes and Recovery	36	First outpatient appointments and proportion of all outpatient appointments	23,053	41%	41%	41%	32%	15%				68%	PBR SUS	2011/12	
	37	NLCA: Median survival in days and adjusted hazard ratio for mortality	176	0.95	0.82	1.11	1.0	0.57				1.49	NLCA	2011	
Patient Experience - CPES (8)	38	NLCA: Proportion of patients surviving at one year and adjusted odds ratio of surviving 1 year	34%	1.43	0.97	2.11	1.0	0.40				2.67	NLCA	2011	
	39	Patients surveyed & % reporting always being treated with respect & dignity (6)	13	n/a			83%	66%				100%	CPES	2011/12	
	40	% Red	0	n/a				0%				78%	CPES	2011/12	
	41	% Green	0	n/a				0%			69%	CPES	2011/12		
	41	Number of survey questions and % of those questions scoring red and green (7)	0	n/a				0%				69%	CPES	2011/12	




# Gleason $\leq 6$ prostate cancers having RP






# Gleason 7 prostate cancers having RP






# Gleason 8+ prostate cancers having RP








# Emergency readmission after RP






# LOS for RP





# TNM stage completeness: bladder cancer






# TNM stage completeness: prostate cancer






# Emergency admissions at EOL: kidney





# Emergency LOS at EOL: kidney





# Emergency LOS at EOL: kidney

